Search Clinical Trials
Sponsor Condition of Interest |
---|
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Schrödinger, Inc.
Acute Myeloid Leukemia
High-Risk and Very High-Risk Myelodysplastic Syndromes
The purpose of this study is to evaluate safety and tolerability and to determine the
maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921. expand
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921. Type: Interventional Start Date: Sep 2023 |
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab)...
Pfizer
Diffuse Large B-Cell Lymphoma
The purpose of this study is to learn about the effects of two study medicines
(maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of
diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means
has returned after last treatment. Refractory... expand
The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine. DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking adult participants who: - Have histologically confirmed diagnosis of DLBCL - Have received at least two first lines of treatment for NHL. - Are unable or unwilling to undergo a stem cell transplant or CAR-T cell therapy. Stem cell transplant is a procedure in which a patient receives healthy blood-forming cells to replace their own stem cells that have been destroyed by treatment. A CAR-T therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. Everyone in this study will receive all three medicines at the study site by intravenous (IV) infusion which is given directly into a vein. The two study medicines (maplirpacept [PF-07901801] and glofitamab) will be given in 21-day cycles. At Cycle 0, participants will receive a single dose of obinutuzumab pre-treatment followed by two step-up doses of glofitamab. The combination of maplirpacept (PF-07901801) with glofitamab full dose will be administered for the first time at Cycle 1 Day 1. Maplirpacept (PF-07901801) will be given weekly for the first three cycles and then every three weeks. Glofitamab will be given every 3 weeks for approximately 9 months. Thereafter participants will continue to receive maplirpacept alone. Maplirpacept (PF-07901801) will be given at different doses to different participants. Everyone taking part will receive the same fixed doses of glofitamab and obinutuzumab studied in patients with DLBCL. The study will compare the experiences of people receiving different doses of maplirpacept (PF-07901801). This will help to determine what dose is safe and effective when given with the other 2 study medicines. Type: Interventional Start Date: Aug 2023 |
SUBLOCADE Long-term Outcomes
Indivior Inc.
Opioid Use Disorder
This study will provide the opportunity to generate data on the long-term use of
SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle,
health, and sociodemographic factors that are part of the recovery process. Long-term
patterns of abstinence/opioid misuse as well as... expand
This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years. Type: Observational Start Date: Aug 2023 |
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants...
Iovance Biotherapeutics, Inc.
Metastatic Melanoma
Unresectable Melanoma
Melanoma
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study
to assess the efficacy and safety of lifileucel in combination with pembrolizumab
compared with pembrolizumab alone in participants with untreated, unresectable or
metastatic melanoma. Participants randomized to... expand
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period. Type: Interventional Start Date: Mar 2023 |
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants...
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension
MSA - Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and
durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks
of treatment. This study includes 4 periods: Screening, open label, randomized
withdrawal, and long-term treatment extension... expand
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE). Type: Interventional Start Date: Jun 2023 |
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
The purpose of this study is to evaluate the safety, and tolerability and efficacy of
VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic
fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR
modulator therapy. expand
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy. Type: Interventional Start Date: Feb 2023 |
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral...
SWOG Cancer Research Network
Malignant Solid Neoplasm
This phase III trial compares the effect of 3 study approaches in preventing
chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous
compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel
or docetaxel, can cause a nerve disorder called peripheral... expand
This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel or docetaxel, can cause a nerve disorder called peripheral neuropathy, which can cause numbness, tingling, or pain in the arms and legs. The 3 study approaches will use a device, called the Paxman Limb Cryocompression System, made of wraps that cool and/or compress the arms and legs. This study may help researchers determine if any of the study approaches are able to prevent taxane chemotherapy from causing peripheral neuropathy. Type: Interventional Start Date: Jun 2023 |
Defining Endpoints in Becker Muscular Dystrophy
Virginia Commonwealth University
Becker Muscular Dystrophy
Muscular Dystrophies
Muscular Dystrophy in Children
Muscular Dystrophy, Becker
This is a 24-month, observational study of 50 participants with Becker muscular dystrophy
(BMD) expand
This is a 24-month, observational study of 50 participants with Becker muscular dystrophy (BMD) Type: Observational Start Date: Apr 2022 |
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal...
Cogent Biosciences, Inc.
Advanced Gastrointestinal Stromal Tumors
Metastatic Cancer
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination
with sunitinib. This is a multi-part study that will enroll approximately 426 patients.
Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of
CGT9486 to be used in subsequent... expand
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner. Type: Interventional Start Date: Apr 2022 |
CureDuchenne Link®: A Resource for Research
CureDuchenne
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and
self- and/or caregiver-reported information from participants. Anyone over 4 weeks old
who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join.
Parents or legal guardians can sign up... expand
CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join. Parents or legal guardians can sign up their child(ren). Type: Observational [Patient Registry] Start Date: Jul 2021 |
Post COVID-19 Biorepository
University of Kansas Medical Center
Coronavirus Infection
Establish a biorepository, clinical data registry, and radiographic image database from
individuals who were COVID positive at one time and are being seen for outpatient
follow-up or a separate study visit. expand
Establish a biorepository, clinical data registry, and radiographic image database from individuals who were COVID positive at one time and are being seen for outpatient follow-up or a separate study visit. Type: Observational [Patient Registry] Start Date: Feb 2021 |
CHIlled Platelet Study "CHIPS"
Philip Spinella
Acute Blood Loss
A phase 3 randomized partial blind storage duration ranging study in patients undergoing
complex cardiac surgery that will compare the transfusion of cold stored platelets to
standard room temperature stored platelets. The primary objective is to establish that
cold stored platelets have a non-inferiority... expand
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets. Type: Interventional Start Date: Oct 2021 |
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in...
National Cancer Institute (NCI)
Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Metastatic Urothelial Carcinoma
This phase III trial compares the usual chemotherapy treatment to eribulin plus
gemcitabine in treating patients with urothelial cancer that has spread to other places
in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel,
paclitaxel, and sacituzumab govitecan work... expand
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer. Type: Interventional Start Date: Jun 2021 |
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants &...
Sonya Heltshe
Cystic Fibrosis
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly
effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their
impact on children with cystic fibrosis (CF). expand
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF). Type: Observational Start Date: Nov 2020 |
Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
BeiGene
Mature B-Cell Malignancies
The purpose of this study is to determine the safety, tolerability; and to define the
maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the
safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417
monotherapy, and when given in combination... expand
The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab. Type: Interventional Start Date: Mar 2020 |
The ENCIRCLE Trial
Edwards Lifesciences
Mitral Regurgitation
Mitral Valve Insufficiency
This study will establish the safety and effectiveness of the SAPIEN M3 System in
subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially
available surgical or transcatheter treatment options are deemed unsuitable.
Following completion of enrollment, subjects will... expand
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial. Type: Interventional Start Date: Nov 2020 |
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation...
Janssen Research & Development, LLC
Multiple Myeloma
The purpose of this study is to evaluate the overall minimal residual disease (MRD)
negative rate of participants who receive JNJ-68284528. expand
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528. Type: Interventional Start Date: Nov 2019 |
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple...
Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with
placebo in participants with primary progressive multiple sclerosis (PPMS), including
participants later in their disease course. This study focuses on upper limit disability
progression. This study will consist... expand
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and B-cell monitoring (BCM). Type: Interventional Start Date: Aug 2019 |
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents...
Celgene
Lymphoma, Non-Hodgkin
The purpose of this study is to evaluate the safety, tolerability, and preliminary
efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants
with relapsed or refractory non-Hodgkin's lymphomas. expand
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas. Type: Interventional Start Date: May 2019 |
Blue Light Cystoscopy With Cysview® Registry
Photocure
Bladder Cancer
Registry study to gather more information on the current use of Blue Light Cystoscopy
with Cysview (BLCC) in urologists' practices. expand
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices. Type: Observational [Patient Registry] Start Date: Apr 2014 |
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants with Myotonic Dystrophy Type 1
PepGen Inc
Myotonic Dystrophy 1
The primary purpose of the study is to evaluate the safety and tolerability of single
intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy
Type 1 (DM1).
The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and
Observation Period... expand
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks). Type: Interventional Start Date: Dec 2023 |
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who...
SWOG Cancer Research Network
AL Amyloidosis
This phase III trial compares the effect of adding a stem cell transplant with melphalan
after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and
dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients
with newly diagnosed amyloid light chain... expand
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patients to replace the blood forming cells that were destroyed by the chemotherapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs, such as cyclophosphamide and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to lower the body's immune response to help stop the growth of cancer cells. Giving a stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in patients with newly diagnosed AL amyloidosis. Type: Interventional Start Date: Jul 2024 |
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated...
Novartis Pharmaceuticals
Coronary Artery Disease
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran,
in comparison to placebo taken in addition to statin medication can effectively reduce
the total amount of plaque formed in the heart's vessels as measured by coronary computed
tomography angiography (CCTA) from... expand
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography angiography (CCTA) from baseline to month 24. This study is being conducted in eligible participants with a diagnosis of non-obstructive coronary artery disease (NOCAD), where the coronary arteries are blocked less than 50%, and with no previous cardiovascular events. Type: Interventional Start Date: Jul 2022 |
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib
works to shrink tumors in patients with solid tumors that are unlikely to be cured or
controlled with treatment and that may have spread from where it first started to nearby
tissue, lymph nodes, or distant parts... expand
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer. Type: Interventional Start Date: Nov 2022 |
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma
Primary CNS Lymphoma
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib
monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in
combination with one of two different high dose methotrexate based regimens
(methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/
vincristine)... expand
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B) Type: Interventional Start Date: Dec 2021 |
- Previous
- Next